Breakthrough treatments for unmet need
About us & Vision
We are a proven leader in the field of rare diseases that are complement-mediated. Our scientists are focused on finding novel therapies for rare diseases in which complement alternative pathway is a key driver of pathogenesis. We focus on therapies that can intervene upstream in the complement system, selectively targeting the pathway underlying the diseases in question.
At NovelMed, we are continuously encouraged and inspired by the needs of patients as we discover game-changing therapies for rare diseases. Every rare disease is unique in itself but the treatment may be similar as they all may fall under a definite class of diseases to be treated by the same drug. Such opportunities are unique for the innovators and drug developers.
At NovelMed, we combine our knowledge base and scientific and clinical strategies in developing novel drugs for rare diseases of the complement system so that we can rapidly develop new drugs for rare diseases with limited or no treatment options not only suitable for one but for many indications driven by the similar mechanism of action. NovelMed has a robust product-driven technology capable of producing a proprietary pipeline of novel therapeutics monoclonal antibodies to diagnose and treat rare diseases.
Our lead product candidate, NM8074, is a first-in-class, anti-Bb antibody that selectively targets the Alternative pathway of the Complement system. This novel antibody drug is currently in clinical development for the treatment of rare diseases specially in complement-mediated disorders including but not limited to hematology, ocular, and inflammatory.
Because numerous rare diseases are caused by the same underlying mechanism treatable by NM8074, there are clear possibilities for therapeutic intervention for other indications categorized under unmet need. FDA approval is straightforward for rare disease platform because approval in one indication would allow us to treat multiple diseases in parallel. Such an attractive technology would ultimately become the investors choice for patients and developers.
The foundation of all our efforts as it is important for patients.
Maintain high ethical standards for our research, services, and communications.
Provide value for patients, healthcare providers, employees, and investors.
Invite best-in-class scientists, inventors and committed people. Provide an environment that fosters honesty, & respect,
To have the First-in-class diagnostics and Novel drugs to treat rare diseases
Science that redefines what is humanly possible to create as a First-in-class medicines.for rare diseases